FDA Says MOBIC Tablets Are Fine, Generics Keep Flowing Smoothly
Published Date: 4/21/2025
Notice
Summary
The FDA says MOBIC tablets (7.5 mg and 15 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved, so patients and pharmacies won’t face shortages or price jumps. If you use or sell MOBIC, things will keep running smoothly with no surprise changes.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Generic MOBIC Approvals Continue
The FDA determined that MOBIC (meloxicam) tablets, 7.5 mg and 15 mg, were not withdrawn from sale for reasons of safety or effectiveness. Because of that finding, the FDA will not start procedures to withdraw approvals of abbreviated new drug applications (ANDAs) that refer to these products and will continue to approve ANDAs that refer to them if they meet legal and regulatory requirements. This lets the FDA keep approving generic versions, helping patients and pharmacies avoid shortages or sudden price increases.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in